Preparing for success with comparative effectiveness research

Oncologist

Volumn 18, Issue 6, 2013, Pages 655-657

  Roberts, Thomas G ^a  

^a LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ACUTE LEUKEMIA; CANCER RESEARCH; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; NEOPLASM; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84879469294     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0213     Document Type: Note

References (16)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011:144;646-74.
2. Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012:12;252-64.
3. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Noti-f ications. Available at: http://www.fda.gov/ Drugs/I nformation On Drugs/Approved Drugs/ ucm279174.htm. Accessed May 28, 2013.
4. Yabroff KR, Lund J, Kepka D et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011:20;2006-14.
5. Hoch JS, Hodgson DC, Earle CC. Role of comparative effectiveness research in cancer funding decisions in Ontario, Canada. J Clin Oncol 2012:30;4262-6.
6. Sorenson C., Drummond M., Chalkidou K. Comparative effectiveness research: the experi ence of the National Institute for Health and Clinical Excellence. J Clin Oncol. 2012:30;4267-74.
7. Neumann PJ, Chambers JD. Medicare's enduring struggle to define "reasonable and necessary" care. N Engl J Med 2012:367;1775-7.
8. Lyman, GH. Comparative Effective-ness Research in Oncology. The Oncologist 2013:18;752-759.
9. Ramsey, SD, Sullivan SD, Reed SD et al. Oncology Comparative Effectiveness Research: A Multistakeholder Perspective on Principles for Conduct and Reporting. The Oncologist 2013:18;760-767.
10. Schrag D. The price tag on progress--chemo-therapy for colorectal cancer. N Engl J Med 2004: 351;317-9.
11. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) 2010:29;1796-804.
12. Pollack A. "Doctors Denounce Cancer Drug Prices of $100,000 a Year. " April 25 2013. Available at: http://www.nytimes.com/2013/04/26/busi-ness/cancer-physicians-attack-high-drug-costs. html?pagewanted=all&_r=0. Accessed on May 28, 2013.
13. Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012:30;1715-24.
14. Lichter AS. Relentless progress: ASCO responds. The Oncologist 2012:17;160-1.
15. Basch E, Somerf ield M, Partridge A et al. Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract 2011: 7; 398-401.
16. Pearson, SD. Cost, coverage, and comparative effectiveness research: the critical issues for oncology. J Clin Oncol 2012:30;4275-81.